Incyte Corporation
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with hepatic impairment.
Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Age 18 to 80 years (inclusive) at the time of signing the ICF. * Moderate or severe hepatic impairment based on Child-Pugh score. * Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory examinations at screening and check-in. * BMI of 18.0 to 44.0 kg/m2 (inclusive) at screening. * Ability to swallow and retain oral tablets. * Willingness to avoid pregnancy or fatherin…
single dose administered orally
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.